Crescent Biopharma, Inc. (CBIO) - 10-K Summary
Business Context and Reporting Period
Company: Crescent Biopharma, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Crescent is a clinical-stage biotechnology company focused on oncology. The company was formed via a reverse recapitalization with GlycoMimetics, Inc., consummated on June 13, 2025, and subsequently redomesticated to the Cayman Islands. The company has no products approved for commercial sale and has not generated revenue from product sales.
Key Pipeline Assets:
- CR-001: A PD-1 x VEGF bispecific antibody. The global Phase 1/2 ASCEND trial was initiated in Q1 2026.
- CR-002: A PD-L1-directed antibody-drug conjugate (ADC). Phase 1/2 trial initiation is anticipated in H2 2026.
- CR-003 (SKB105): An ITGB6-directed ADC licensed from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun"). Phase 1/2 trial initiation in China is anticipated in Q1 2026.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (in millions) | 2024 (Inception to Dec 31) |
|---|---|---|
| License Revenue | $10.8 | $0.0 |
| Total Operating Expenses | $163.5 | $17.2 |
| Net Loss | $(153.9) | $(17.9) |
| Cash and Cash Equivalents (Ending) | $213.2 | $34.8 |
| Net Cash Used in Operating Activities | $(71.5) | $(6.3) |
| Net Cash Provided by Financing Activities | $323.0 | $41.0 |
Capital Structure: As of December 31, 2025, the company had 27,556,767 ordinary shares outstanding. The company raised approximately $185.0 million in a private placement in December 2025 and approximately $200.0 million in pre-closing financing in June 2025.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $10.8 million in license revenue in 2025, primarily from the upfront payment received from Kelun for the exclusive license to CR-001 in Greater China. No revenue was recognized in 2024.
- Expense Surge: Operating expenses increased significantly from $17.2 million in 2024 to $163.5 million in 2025. This was driven by a $78.2 million non-cash charge for the upfront license fee for CR-003 (SKB105) from Kelun and increased R&D activities for CR-001 and CR-002.
- Liquidity Position: Cash and cash equivalents increased from $34.8 million to $213.2 million due to significant equity financings (Pre-Closing Financing and Private Placement) and the reverse recapitalization.
- Corporate Structure: The company completed a reverse recapitalization with GlycoMimetics and redomesticated to the Cayman Islands in June 2025.
Guidance, Outlook, and Risks
Outlook and Milestones:
- The company anticipates reporting proof-of-concept clinical data from the CR-001 ASCEND trial in Q1 2027.
- Initiation of CR-002 and CR-003 monotherapy trials and the first CR-001/ADC combination trial are expected in 2026.
- Management expects existing cash resources to fund operations for at least 12 months from the filing date.
Key Risks and Contingencies:
- Capital Requirements: The company has a history of losses and expects to continue incurring significant losses. It will require substantial additional capital to fund clinical trials and operations.
- Development Risk: Success is heavily dependent on the clinical performance of CR-001, CR-002, and CR-003. There is no assurance that clinical trials will be successful or that regulatory approval will be obtained.
- Intellectual Property: The company does not currently own any issued patents; its portfolio relies on in-licenses from Paragon Therapeutics and Kelun.
- Third-Party Reliance: The company relies on third parties for manufacturing (e.g., WuXi Biologics) and clinical trial conduct. Geopolitical risks involving China-based partners (Kelun, WuXi) are highlighted, including potential impacts from the BIOSECURE Act.
- Related Party Transactions: Significant relationships exist with Paragon Therapeutics (licensing) and Fairmount Funds Management (significant shareholder and board representation).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $213.2 million cash balance against the projected burn rate for 2026-2027 clinical trials.
- CR-001 Clinical Data: Monitor the Q1 2027 data readout from the ASCEND trial for safety and early efficacy signals.
- Kelun Partnership: Review the terms of the Kelun collaboration, specifically the $80 million upfront payment for CR-003 and the revenue-sharing mechanics for CR-001 in Greater China.
- Paragon Termination: Confirm the status of the termination of the ADC Paragon Option Agreement (effective March 2026) and the transition of the CR-003 program to the Kelun asset.
- Regulatory Filings: Track the submission of INDs for CR-002 and CR-003 and the initiation of the first ADC combination trial.